相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacogenetic studies in Alzheimer disease
T. Zuniga Santamaria et al.
NEUROLOGIA (2022)
Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of Donepezil and Its Metabolite in Patients With Alzheimer Disease
Yoshiyuki Kagawa et al.
THERAPEUTIC DRUG MONITORING (2021)
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
Kelly E. Caudle et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy
Jin Lu et al.
FRONTIERS IN PHARMACOLOGY (2020)
Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil
Marion Ortner et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics
Miriam Saiz-Rodriguez et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2019)
Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation
Sean D. Kodani et al.
BIOCHIMIE (2019)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Zeruesenay Desta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention
Miriam Saiz-Rodriguez et al.
CLINICAL THERAPEUTICS (2019)
Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease
Chirag N. Patel et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2018)
Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors
Ezio Giacobini et al.
CURRENT ALZHEIMER RESEARCH (2018)
Mechanism of NMDA receptor channel block by MK-801 and memantine
Xianqiang Song et al.
NATURE (2018)
Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers
Miriam Saiz-Rodriguez et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Pharmacogenetics of Vascular Risk Factors in Alzheimer's Disease
Ramon Cacabelos et al.
JOURNAL OF PERSONALIZED MEDICINE (2018)
Donepezil for dementia due to Alzheimer's disease
Jacqueline S. Birks et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2018)
Role of Glutamate and NMDA Receptors in Alzheimer's Disease
Rui Wang et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment
Sophie Sokolow et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Systematic Review of Sex-Specific Reporting of Data: Cholinesterase Inhibitor Example
Nishila Mehta et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2017)
The role of BDNF in Alzheimer's disease
Heikki Tanila
NEUROBIOLOGY OF DISEASE (2017)
Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials
Marco Canevelli et al.
PHARMACOLOGICAL RESEARCH (2017)
Memantine inhibits β-amyloid aggregation and disassembles preformed β-amyloid aggregates
Kaori Takahashi-Ito et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system
Carmelo Aguirre et al.
MEDICINA CLINICA (2016)
Influence of four polymorphisms in ABCA1 and PTGS2 genes on risk of Alzheimer's disease: a meta-analysis
Qicong Chen et al.
NEUROLOGICAL SCIENCES (2016)
MEMANTINE AND DONEPEZIL: A FIXED DRUG COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DEMENTIA
R. T. Owen
DRUGS OF TODAY (2016)
Association of the Choline Acetyltransferase Gene with Responsiveness to Acetylcholinesterase Inhibitors in Alzheimer's Disease
H. Yoon et al.
PHARMACOPSYCHIATRY (2015)
Effect of APOE and CHRNA7 Genotypes on the Cognitive Response to Cholinesterase Inhibitor Treatment at Different Stages of Alzheimer's Disease
Ianna Lacerda Sampaio Braga et al.
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS (2015)
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance
Muriel Noetzli et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing
K. E. Caudle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease
Renato Scacchi et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2014)
Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors
Muriel Noetzli et al.
CLINICAL PHARMACOKINETICS (2013)
Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer's Disease
Muriel Noetzli et al.
CLINICAL PHARMACOKINETICS (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer's Disease
Chris G. Parsons et al.
NEUROTOXICITY RESEARCH (2013)
Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with Alzheimer's disease
Aleksandra Klimkowicz-Mrowiec et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2013)
Missense substitutions associated with behavioural disturbances in Alzheimer's disease (AD)
Petroula Proitsi et al.
BRAIN RESEARCH BULLETIN (2012)
Memantine in dementia: a review of the current evidence
Nathan Herrmann et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Plasma Concentration of Donepezil to the Therapeutic Response of Alzheimer's Disease in Taiwanese
Yuan-Han Yang et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease
Davide Seripa et al.
PHARMACOGENETICS AND GENOMICS (2011)
Pharmacogenomic Protocols in CNS Disorders and Dementia
Ramon Cacabelos
NEURODEGENERATIVE DISEASES (2010)
Update on the use of memantine in Alzheimer’s disease
Rob Marum
Neuropsychiatric Disease and Treatment (2010)
Variability of AChE, BChE, and ChAT Genes in the Late-Onset Form of Alzheimer's Disease and Relationships With Response to Treatment With Donepezil and Rivastigmine
Renato Scacchi et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2009)
Memantine A Review of its Use in Moderate to Severe Alzheimer's Disease
Kate McKeage
CNS DRUGS (2009)
Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development
S. -F. Zhou et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
Alberto Pilotto et al.
NEUROLOGY (2009)
Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease
T. Leyhe et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2008)
Memantine agonist action at dopamine D2High receptors
Philip Seeman et al.
SYNAPSE (2008)
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
Rafael Blesa et al.
PHARMACOGENETICS AND GENOMICS (2006)
SNPStats:: a web tool for the analysis of association studies
Xavier Sole et al.
BIOINFORMATICS (2006)
Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: Implications for Tourette's syndrome
RL Hayslett et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2005)
Dementia of Alzheimer's disease and other neurodegenerative disorders - memantine, a new hope
SK Sonkusare et al.
PHARMACOLOGICAL RESEARCH (2005)
Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene
D Craig et al.
NEUROSCIENCE LETTERS (2004)
Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions
S Micuda et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner
G Rammes et al.
NEUROSCIENCE LETTERS (2001)
分享论文
